Targeted therapy plus chemo for advanced pancreatic cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a new targeted drug called sotorasib combined with standard chemotherapy for people with advanced pancreatic cancer that has a specific KRAS G12C mutation. The goal is to see if the combination works better than chemotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and willing to give informed consent.
- You have a specific type of pancreatic cancer (called KRAS G12C positive) that is locally advanced or has spread to other parts of the body.
- You have not had any prior chemotherapy for this advanced cancer (except possibly a short course of standard treatment while waiting for study enrollment).
- You are able to swallow pills, keep a daily medication diary, and have adequate organ function as shown by blood tests.
- You are not pregnant or breastfeeding, and you agree to use effective contraception if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted radiation and two oral drugs (defactinib and avutometinib) for people with advanced pancreatic cancer that hasn't spread to distant organs. It may be an option if you've already had at least 2 months of chemo and your cancer is still locally advanced or borderline resectable.
This trial tests whether adding a new drug called zoldonrasib to standard chemotherapy works better than chemotherapy alone for pancreatic cancer that has spread and has a specific KRAS G12D mutation. The goal is to see if this combination helps patients live longer and control their cancer better.
This trial is testing a combination of two targeted drugs (panitumumab and sotorasib) with a chemotherapy drug (5-fluorouracil) for people with advanced colorectal cancer that has a specific KRAS G12C mutation and who cannot receive stronger chemotherapy. It aims to see if this treatment can help control the cancer.
This trial tests three new targeted drug combinations for pancreatic cancer that has a specific genetic change (KRAS G12D). They are comparing the study drug alone versus combining it with other investigational drugs to see which works better.
This trial tests a new medicine (DN022150) combined with standard chemotherapy as a first treatment for advanced pancreatic cancer that has a specific genetic change called KRAS G12D. The combination may help shrink or slow the cancer better than chemotherapy alone.
This trial tests a combination of three chemotherapy drugs (mFOLFIRINOX) along with anlotinib (a targeted therapy) and sintilimab (an immunotherapy) for people with advanced pancreatic cancer who have not had prior treatment. The goal is to see if this combination can help shrink tumors or slow the disease.
Hear when a new Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.